EUCTR2007-005460-28-GR进行中（未招募）不适用
An open-label, multi-center, expanded access study of RAD001 in patients with metastatic carcinoma of the kidney who have progressed despite vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Age = 18 years old.
- •Patients with metastatic carcinoma and with histological or cytological confirmation of clear cell RCC (tissue from the original diagnosis of renal cell cancer is acceptable).
- •Patients must have progression on or after stopping treatment with any component of VEGF receptor tyrosine kinase inhibitor therapy (sunitinib and/or sorafenib).
- •Prior vaccine therapy or treatment with cytokines (i.e., IL-2, Interferon) and/or VEGF-ligand inhibitors (i.e., bevacizumab) is permitted.
- •Patients with measurable or non-measurable disease by RECIST criteria.
- •Patients with history of another distinguishable malignancy (such as non-melanoma skin cancer, or low grade lymphoma, or CLL, or well controlled low grade prostate cancer), which are neither life threatening nor require chemotherapy or radiation.
- •Patients with history of brain metastasis who are neurologically stable following definitive radiation or surgery and do not require corticosteroids.
- •Patients with a Karnofsky Performance Status =70%.
- •Patients with adequate bone marrow function defined as ANC = 1.5 x 109/L, Platelets = 100 x 109/L, Hgb >9 g/dL.
- •Patients with adequate liver function defined as serum bilirubin = 1.5 x ULN, ALT and AST = 2.5x ULN. Patients with known liver metastases who have an AST and ALT = 5x ULN.
- •Patients with adequate renal function defined as serum creatinine = 2 x ULN.
- •Women of childbearing potential must have had a negative serum or urine pregnancy test within 14 days prior to the administration of study drug.
- •Patients must give written informed consent according to local guidelines.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients receiving chemotherapy, immunotherapy, radio-therapy or any other investigational agent within 4 weeks of study entry, or sunitinib and/or sorafenib within 1 week of the first dose of RAD001.
- •Patients who have previously received RAD001 or other mTOR inhibitors.
- •Patients with a known hypersensitivity to RAD001 or other rapamycin analogs (sirolimus, temsirolimus), or to its excipients.
- •Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent (except corticosteroids with a daily dosage equivalent to prednisone = 20 mg for adrenal insufficiency). Patients receiving corticosteroids must be on a stable dose = 4 weeks prior to the first dose of RAD001. Topical or inhaled corticosteroids are permitted.
- •Patients with an active bleeding diathesis.
- •Patients with any severe and/or uncontrolled medical conditions such as unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction = 6 months, serious uncontrolled cardiac arrhythmia, uncontrolled hyperlipidemia, active or uncontrolled severe infection, cirrhosis, chronic or persistent active hepatitis or severely impaired lung function.
- •Uncontrolled diabetes (fasting glucose > 2x ULN)
- •Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods. If barrier contraceptives are used, they must be continued throughout the study by both sexes.
- •Patients unwilling to or unable to comply with the protocol.
研究者
相似试验
已完成
3 期
An open-label, multi-center, expanded access study of parireotide s.c. in patients with Cushing's disease (CSOM230B2406) (SEASCAPE)Cushing's disease10021112NL-OMON39474ovartis Pharma BV2
已完成
3 期
An open-label, multi-center, expanded access study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer who have progressed following prior endocrine therapy, investigating the treatment of everolimus (RAD001) in combination with exemestane10006291breast cancerNL-OMON37575ovartis Pharma BV180
进行中（未招募）
不适用
An open-label, multi-center, expanded access study of RAD001 in patients with subependymal giant cell astrocytomas (SEGA) associated with tuberous sclerosis complex (TSC). The EFFECTS STUDY: Everolimus For Fast Expanded aCcess in TSC SEGA - EFFECTS STUDYEUCTR2010-022583-13-HUovartis Pharma Services AG250
进行中（未招募）
不适用
An expanded access study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer who have progressed following prior endocrine therapy, investigating the treatment of everolimus (RAD001) in combination with exemestaneEUCTR2012-000073-23-ATovartis Pharma Services AG2,200
进行中（未招募）
不适用
An open-label, multi-center, expanded access study of everolimus in patients with advanced neuroendocrine tumorsEUCTR2010-023032-17-CZovartis Pharma Services AG200